Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serranator OCT
NCT06434194Recruiting
- Sponsor
- Cagent Vascular
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in critical limb ischemia (CLI) (2 arms), sponsored by Cagent Vascular. Primary endpoint: Residual Lumen Volume Stenosis. Started Oct 2024; status: recruiting.
02
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06434194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434194.